Compare Charter Communications Inc (CHTR) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charter Communications Inc vs Medpace Holdings Inc — how do they compare? Charter Communications Inc trades at $156.89 (market cap $18.81B), while Medpace Holdings Inc trades at $607 (market cap $16.90B). The key difference: Charter Communications Inc and Medpace Holdings Inc are close in size by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Charter Communications Inc nearer its low. Which is the better fit depends on your goals.
| CHTR | MEDP | |
|---|---|---|
Market Cap | $18.81B | $16.90B |
Sector | Media | Technology |
52-Week High | $282.74 | $620.59 |
52-Week Low | $123.31 | $393.42 |
Enterprise Value | $115.01B | $16.52B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charter Communications Inc
Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 54 million U.S. homes and businesses, around 40% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest U.S. cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.
Read more on CHTR →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
